SecuritySYNL / Synalloy Corp. (871565107)
Institutional Owners46 (10 N-Q Owners)
Institutional Shares4,369,692 - 49.90% (ex. N-Q)
Common Shares Outstanding8,757,434 shares (as of 2017-12-31)
Institutional Value$ 702,060,000 USD (ex. N-Q)

Institutional Stock Ownership and Shareholders

Synalloy Corp. (NASDAQ:SYNL) has 46 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 4,369,692 shares. Largest shareholders include Royce & Associates LLC, Deprince Race & Zollo Inc, Van Den Berg Management I, Inc, Markel Corp, Dimensional Fund Advisors Lp, Vanguard Group Inc, 22nw, Lp, Renaissance Technologies LLC, GAM Holding AG, and BlackRock Inc..
Synalloy Corp. (NASDAQ:SYNL) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR Brandywine Global Investment Management, LLC 6,144 4,973 -19.06 83 73 -12.05
2018-01-29 N-Q Cm Advisors Family Of Funds (see advisory)
2018-05-11 13F-HR Delpha Capital Management, Llc 144 0 -100.00 2 0 -100.00
2018-01-26 N-Q Trust For Professional Managers (see advisory)
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 0 1,800 0 26
2018-03-27 N-Q Nationwide Mutual Funds (see advisory)
2018-05-15 13F-HR UBS Group AG 646 81 -87.46 9 1 -88.89
2018-05-14 13F-HR Royce & Associates LLC 913,509 958,753 4.95 12,241 13,758 12.39
2018-02-28 N-Q Ishares Trust (see advisory)
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 407,110 412,620 1.35 5,455 5,921 8.54
2018-05-10 13F-HR Minerva Advisors LLC 84,755 84,755 0.00 1,128 1,212 7.45
2018-02-27 N-Q Northern Funds (see advisory)
2018-03-27 N-Q PRINCIPAL FUNDS INC (see advisory)
2018-05-15 13F-HR SALEM INVESTMENT COUNSELORS INC 5 0 -100.00 0 0
2018-04-18 13F-HR DEPRINCE RACE & ZOLLO INC 494,133 486,669 -1.51 6,621 7,105 7.31
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 38,040 38,040 0.00 509 545 7.07
2018-05-14 13F-HR NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 4,000 4,000 0.00 54 58 7.41
2018-05-14 13F-HR FARR MILLER & WASHINGTON LLC/DC 99,568 99,568 0.00 1,334 1,454 9.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 0 348 0 5
2018-05-17 13F-HR Atlantic Trust Group, LLC 1,920 28
2018-04-25 N-Q Unified Series Trust (see advisory)
2018-04-27 13F-HR MARKEL CORP 414,804 414,804 0.00 5,558 6,056 8.96
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 2,190 1,671 -23.70 29 24 -17.24
2018-05-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 85 1
2018-05-15 13F-HR 22NW, LP 247,502 248,111 0.25 3,317 3,622 9.20
2018-02-08 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 683 0 -100.00 9 0 -100.00
2018-05-15 13F-HR Bank of New York Mellon Corp 21,325 24,471 14.75 286 357 24.83
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 8,598 8,387 -2.45 116 122 5.17
2018-02-13 13F-HR O'SHAUGHNESSY ASSET MANAGEMENT, LLC 7,158 0 -100.00 89 0 -100.00
2018-02-14 13F-HR GSA CAPITAL PARTNERS LLP 11,701 0 -100.00 146 0 -100.00
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 26 1,418 5,353.85 0 21
2018-05-15 13F-HR FIRST WILSHIRE SECURITIES MANAGEMENT INC 62,414 60,889 -2.44 836 889 6.34
2018-05-14 13F-HR MORGAN STANLEY 4,900 4,900 0.00 66 71 7.58
2018-02-28 N-Q Wisdomtree Trust (see advisory)
2018-05-15 13F-HR VAN DEN BERG MANAGEMENT I, INC 496,310 481,434 -3.00 6,651 7,029 5.68
2018-05-04 13F-HR MORGAN DEMPSEY CAPITAL MANAGEMENT LLC 45,887 43,898 -4.33 614,886 639,429 3.99
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 112,600 89,600 -20.43 1,509 1,286 -14.78
2018-05-15 13F-HR GAM Holding AG 150,000 150,000 0.00 2,010 2,153 7.11
2018-02-15 13F-HR Fieldpoint Private Securities, LLC 1,209 0 -100.00 15 0 -100.00
2018-05-14 13F-HR Pin Oak Investment Advisors Inc 255 255 0.00 3 4 33.33
2018-02-01 13F-HR Nationwide Fund Advisors 400 0 -100.00 5 0 -100.00
2018-05-14 13F-HR RAYMOND JAMES & ASSOCIATES 17,500 17,500 0.00 235 256 8.94
2018-05-09 13F-HR NORTHERN TRUST CORP 24,431 21,104 -13.62 327 308 -5.81
2018-04-27 N-Q Fidelity Concord Street Trust (see advisory)
2018-02-14 13F-HR Mill Road Capital Management LLC 149,798 0 -100.00 1,354 0 -100.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 44,857 44,857 0.00 601 644 7.15
2018-05-14 13F-HR KENNEDY CAPITAL MANAGEMENT, INC. 0 19,937 0 291
2018-04-27 N-Q Valic Co I (see advisory)
2018-05-15 13F-HR VANGUARD GROUP INC 288,202 290,220 0.70 3,862 4,164 7.82
2018-04-30 13F-HR TCI Wealth Advisors, Inc. 685 685 0.00 9 10 11.11
2018-02-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 13,400 0 -100.00 168 0 -100.00
2018-05-09 13F-HR BlackRock Inc. 137,204 134,085 -2.27 1,839 1,957 6.42
2018-05-14 13F-HR Renaissance Technologies LLC 179,500 172,794 -3.74 2,405 2,523 4.91
2018-05-15 13F-HR DEUTSCHE BANK AG\ 20,795 13,943 -32.95 278 203 -26.98
2018-05-08 13F-HR US BANCORP \DE\ 30,015 31,117 3.67 401 454 13.22

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.

Limitations:

  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( SYNL / Synalloy Corp. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

10 Little-Known Stocks That Could Be Huge | InvestorPlace

2018-05-18 investorplace
The 10-year U.S. Treasury has crossed the rubicon. It is now flashing a yield that is over the 3% mark. What befalls the economy when that happens? Recession? Correction? A grinding bear market? (6-1)

Synalloy's (SYNL) CEO Craig Bram on Q1 2018 Results - Earnings Call Transcript

2018-05-06 seekingalpha
Good day, ladies and gentlemen, and welcome to Synalloy first quarter's earnings conference call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at the time. [Operator Instructions] I would now like to turn the conference over to Craig Bram, President and CEO. You may begin, sir. (1-0)

Synalloy's (SYNL) CEO Craig Bram on Q4 2017 Results - Earnings Call Transcript

2018-03-13 seekingalpha
Good day, ladies and gentlemen, and welcome to the Synalloy Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]. As a reminder, this conference call may be recorded. (1-0)

CUSIP: 871565107